Symbol="KOD"
AssetType="Common Stock"
Name="Kodiak Sciences Inc"
Description="Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing, and marketing therapies to treat retinal diseases in the United States and international markets. The company is headquartered in Palo Alto, California."
CIK="1468748"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="2631 HANOVER STREET, PALO ALTO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="381677000"
EBITDA="-312919008"
PERatio="None"
PEGRatio="None"
BookValue="7.54"
DividendPerShare="0"
DividendYield="0"
EPS="-6.24"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.269"
ReturnOnEquityTTM="-0.624"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-6.24"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="12.25"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.795"
EVToRevenue="-"
EVToEBITDA="0.197"
Beta="1.753"
num_52WeekHigh="12.8"
num_52WeekLow="2.77"
num_50DayMovingAverage="7.07"
num_200DayMovingAverage="6.78"
SharesOutstanding="52356000"
DividendDate="None"
ExDividendDate="None"
symbol="KOD"
open="3.03"
high="4.07"
low="2.77"
price="3.94"
volume="20545770.00"
latest_trading_day="2023-07-24"
previous_close="7.29"
change="-3.35"
change_percent="-45.8848%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="58"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="TRUE"
Aroon_momentum="42"
Volume_recent_avg="782374"
Change_recent_avg="0.01"
Delta_recent_avg="0.53"
Variance_recent_avg="0.26"
Change_ratio_recent_avg="-0.05"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="TRUE"
Aroon_momentum_positive="42"
Aroon_momentum_negative="58"
image_negative_thumbnail_id_1="126"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0050.jpeg"
image_negative_thumbnail_id_2="1117"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0150.jpeg"
image_neutral_thumbnail_id_1="527"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0072.jpeg"
image_neutral_thumbnail_id_2="598"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0001.jpeg"
image_positive_thumbnail_id_1="957"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0119.jpeg"
image_positive_thumbnail_id_2="669"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0039.jpeg"
image_professor_thumbnail_id_1="1188"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0022.jpeg"
image_professor_thumbnail_id_2="1185"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0019.jpeg"
